B cells are a major component of the tumour microenvironment, where they are
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …

Although immunotherapy research to date has focused largely on T cells, there is mounting
evidence that tumour-infiltrating B cells and plasma cells (collectively referred to as tumour …

Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …

Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat
non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) …

The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention
on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune …

The tumor microenvironment (TME) is a heterogeneous, complex organization composed of
tumor, stroma, and endothelial cells that is characterized by cross talk between tumor and …

The generation of anti-tumor immunity in the draining lymph nodes is known as the cancer
immunity cycle. Accumulating evidence supports the occurrence of such a cycle at tumor …

Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50
histological subtypes,. The clinical presentation of patients with different subtypes is often …

Tertiary lymphoid structures (TLSs) are ectopic lymphoid organs that develop in non-
lymphoid tissues at sites of chronic inflammation including tumours. Key common …

The role and importance of neutrophils in cancer has become increasingly apparent over
the past decade. Neutrophils accumulate in the peripheral blood of patients with cancer …